ASPIRE BIOPHARMA HOLDINGS, INC. Earnings Per Share (Basic)
ASPIRE BIOPHARMA HOLDINGS, INC. (ASBP) reported Earnings Per Share (Basic) of -$1.22 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-13
- ASPIRE BIOPHARMA HOLDINGS, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$1.22.
- ASPIRE BIOPHARMA HOLDINGS, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$20.57.
- ASPIRE BIOPHARMA HOLDINGS, INC. earnings per share, basic for the quarter ending 2025-12-31 was $0.04, a 275.60% increase year-over-year.
- ASPIRE BIOPHARMA HOLDINGS, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.04.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.22 10-Q · filed 2026-08-13 | -$7.49 10-Q · filed 2026-08-13 | $0.21 derived: net income ÷ weighted average shares · filed 2026-08-13 | $0.55 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2026-03-31 | -$20.57 10-Q · filed 2026-05-15 | $0.12 derived: net income ÷ weighted average shares · filed 2026-08-13 | $0.36 derived: net income ÷ weighted average shares · filed 2026-08-13 | $0.58 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-12-31 | $0.04 derived: net income ÷ weighted average shares · filed 2026-04-10 | $0.16 derived: net income ÷ weighted average shares · filed 2026-04-10 | $0.31 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$16.38 derived: net income ÷ weighted average shares · filed 2026-04-10 |
| 2025-09-30 | -$0.04 10-Q · filed 2025-11-14 | -$0.15 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.43 10-Q · filed 2025-11-14 | $2.70 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-06-30 | -$48.19 10-Q · filed 2026-08-13 | -$492.24 10-Q · filed 2026-08-13 | $0.70 derived: net income ÷ weighted average shares · filed 2026-08-13 | $1.44 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-03-31 | -$504.88 10-Q · filed 2026-05-15 | $0.42 derived: net income ÷ weighted average shares · filed 2026-08-13 | $0.97 derived: net income ÷ weighted average shares · filed 2026-08-13 | |
| 2024-12-31 | $0.01 derived: net income ÷ weighted average shares · filed 2026-04-08 | $0.04 derived: net income ÷ weighted average shares · filed 2026-04-08 | -$1.90 derived: net income ÷ weighted average shares · filed 2026-04-10 | |
| 2024-09-30 | -$0.01 10-Q · filed 2025-11-14 | -$0.02 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |